Search

Your search keyword '"Legg, J."' showing total 816 results
Start Over Author "Legg, J."
816 results on '"Legg, J."'

8. New River Gorge

Author

Legg, J. Scott., Fayette County Chamber of Commerce (W. Va.), and Legg, J. Scott.

Published
2010

13. 170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study

Author

Griese, M., primary, Tullis, E., additional, Chilvers, M., additional, Fabrizzi, B., additional, Jain, R., additional, Legg, J., additional, Mall, M., additional, McKone, E., additional, Polineni, D., additional, Poplawska, K., additional, Robinson, P., additional, Taylor-Cousar, J., additional, Ahluwalia, N., additional, Doolittle, C., additional, Jennings, M., additional, Moskowitz, S., additional, Prieto-Centurion, V., additional, Tan, Y.V., additional, Tian, S., additional, Vinarsky, V., additional, Weinstock, T., additional, Xuan, F., additional, Ramsey, B., additional, and Daines, C., additional

Published
2022
Full Text
View/download PDF

21. Metropolitan Universities and the Culture of Research.

Author

Legg, J. Ivan

Abstract

Metropolitan research universities are at the vanguard in addressing current challenges to society. They are successful because they can integrate service and outreach into their mission. To enhance their role, universities should encourage and reward those who can make contributions outside the traditional research model.(JB)

Published
1994

29. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Author

Teerlink, J. R., Diaz, R., Michael Felker, G., Mcmurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sorensen, T., Bohm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlstrom, U., Echeverria, L. E., Fang, J. C., Filippatos, G., Fonseca, C., Goncalvesova, E., Goudev, A. R., Howlett, J. G., Lanfear, D. E., Li, J., Lund, M., Ambrosio, G., Carluccio, E., Macdonald, P., Mareev, V., Momomura, S., O'Meara, E., Parkhomenko, A., Ponikowski, P., Ramires, F. J. A., Serpytis, P., Sliwa, K., Spinar, J., Suter, T. M., Tomcsanyi, J., Vandekerckhove, H., Vinereanu, D., Voors, A. A., Yilmaz, M. B., Zannad, F., Sharpsten, L., Legg, J. C., Varin, C., Honarpour, N., Abbasi, S. A., Malik, F. I., Kurtz, C. E., and Cardiovascular Centre (CVC)

Subjects
Cardiac function curve, Male, medicine.medical_specialty, animal structures, Cardiotonic Agents, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Cardiac Myosins, Internal medicine, medicine, 80 and over, Humans, Urea, 030212 general & internal medicine, Aged, Aged, 80 and over, Heart Failure, Ejection fraction, business.industry, Cardiac myosin, Stroke Volume, General Medicine, Stroke volume, Middle Aged, medicine.disease, R1, Myocardial Contraction, 3. Good health, Omecamtiv mecarbil, Cardiovascular Diseases, Heart failure, cardiovascular system, Cardiology, Female, business, Heart Failure, Systolic, Systolic
Abstract

From: New England Journal of Medicine, Teerlink, JR, Diaz, R, Felker, G, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure, 384(2):105-116. Copyright © 2020. Massachusetts Medical Society. Reprinted with permission. [Abstract] BACKGROUND. The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS. We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS. During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P=0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro–B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS. Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.)

Published
2020
Full Text
View/download PDF

30. Plant resistance to geminiviruses

Author

Basavaprabhu L., Supriya Chakraborty P., Czosnek H., Fiallo-Olivé, Elvira, Gilbertson R.L., Legg J., Mansoor S., Navas-Castillo, Jesús, Naqvi R.Z., Rahman S.U., and Zerbini F.M.

Subjects
fungi, food and beverages, geminivurs resistance
Abstract

Geminiviruses cause major damage to crop plants and evolve through mutations, recombination and pseudo-recombination, expanding their host range and becoming pandemic due to international trade and invasive vector species. Management of geminiviruses consists of breeding resistant crops by employing natural resistance genes from different cultivated or related wild plant species. Compared to other plant viruses, such as potyviruses, the information on resistance genes/loci identified for geminiviruses is scarce. Other strategies have been developed based on the virus genome; however, these have not yet reached the commercial field. Here we catalog and describe the resistance genes/loci identified against the most important geminiviruses, in the most economically important crops they infect: cassava, tomato, bean, maize and cotton.

Published
2020

31. Plant resistance to geminiviruses

Author

https://orcid.org/0000-0002-8616-6241, https://orcid.org/0000-0002-2460-1199, Basavaprabhu, L., Supriya Chakraborty, P., Czosnek, Henrik, Fiallo-Olivé, Elvira, Gilbertson, R. L., Legg, J., Mansoor, S., Navas-Castillo, Jesús, Naqvi R.Z., Rahman S.U., Zerbini F.M., https://orcid.org/0000-0002-8616-6241, https://orcid.org/0000-0002-2460-1199, Basavaprabhu, L., Supriya Chakraborty, P., Czosnek, Henrik, Fiallo-Olivé, Elvira, Gilbertson, R. L., Legg, J., Mansoor, S., Navas-Castillo, Jesús, Naqvi R.Z., Rahman S.U., and Zerbini F.M.

Abstract

Geminiviruses cause major damage to crop plants and evolve through mutations, recombination and pseudo-recombination, expanding their host range and becoming pandemic due to international trade and invasive vector species. Management of geminiviruses consists of breeding resistant crops by employing natural resistance genes from different cultivated or related wild plant species. Compared to other plant viruses, such as potyviruses, the information on resistance genes/loci identified for geminiviruses is scarce. Other strategies have been developed based on the virus genome; however, these have not yet reached the commercial field. Here we catalog and describe the resistance genes/loci identified against the most important geminiviruses, in the most economically important crops they infect: cassava, tomato, bean, maize and cotton.

Published
2020

43. Abstracts of Papers Presented at The International Workshop onBemisia Spp.: October 3–7, 1994 Shoresh Hotel and Conference Center, Shoresh, Israel

Author

Perring, Thomas M., Nelson, D. R., Buckner, J. S., Frohlich, D. R., Brown, J. K., Hong, W. Lei, Tjallingii, Freddy, Lenteren, Joop C. van, Rosell, R. C., Bedford, I. D., Markham, P. G., Guershon, Moshe, Gerling, Dan, Salas, Jorge, Mendoza, Omar, Cebrian, R., Carnero, A., Pérez-Padrón, F., Byrne, David N., Blackmer, Jacquelyn L., Rathman, Robin J., Kasterstein), Esther Weisz, Fasulo, Thomas R., Riley, D. G., Allen, J. C., Brewster, C. C., Paris, J. F., Summers, C. G., Riley, D. G., Naranjo, S. E., Ellsworth, P. C., Diehl, J., Dennehy, T., Flint, H., Carnerol, A., González-Andujar, J. L., Peterling, O., Helman, S., Rumei, Xu, Legg, J., Fishpool, L., Natwick, E. T., Toscano, N. C., Yates, L., Hendrix, Donald L., Steele, Terry, Bar, H., Weinberg, A., Mor, U., Oetting, Donald D., Schuster, David J., Stansly, Philip A., Shapiro, Jeffrey P., Duffus, James E., Harris, K., Esbroeck, Z. Pesic-Van, Hiebert, E., Abouzid, A., Polston, J. E., Liu, S., Pinner, M., Briddon, R. W., Brown, J. K., Bird, J., Wyatt, S. D., Antignus, Y., Adler, O., Perlsman, Melanie, Joseph, Rachel Ben, Cohen, S., Serra, C., Conception, S., Polston, J., Ortiz, M., Benoit, P., Klaassen, Vicki A., Boeshore, Maury, Koonin, Eugene V., Tian, Tongyan, Falk, Bryce W., Cohen, J., Gera, A., Ecker, R., Gokkes, M., Fauquet, Claude M., Sangare, Abdourahamane, Deng, Dalun, Fux, Charles, Beachy, Roger N., Scott, J. W., Schuster, D. J., Barten, J. H. M., Stevens, M. R., Thome, C. H., Chambliss, O. L., Muniyappa, V., Nateshan, H. M., Jalikop, S. H., Chennarayappa, Ramappa, H. K., Raccah, B., Cheek, S., Nordlund, Donald A., Legaspi, Jesusa C., Dean, D. E., Schelt, J. van, Meyerdirk, D. E., Hennessey, R. D., Wendel, L., Goolsby, John, Ciomperlik, Matt, Vecek, Don, Kirk, A. A., Lacey, L. A., Heinz, K. M., Contreras, M., Hoelmer, K. A., Brasch, Klara, Henter, Heather, Minkenberg, Oscar, Kaltenbach, John, Leonard, Catie, Malloy, Richard, Simmons, Gregory, Ziegweid, Katie, Rose, M., Zolnerowich, G., Hunter, M. S., Oster, Noga, Arno, Judit, Gabarra, Rosa, Steinberg, S., Prag, H., Carruthers, R., Fransen, J. J., Barash, I., Mor, H., Gindin, G., Ben-Ze’ev, I., Ben-Ze’ev, I. S., Peterkin, Dorothy D., Hall, Richard A., Horowitz, A. R., Ishaaya, I., Denholm, I., Cahill, M. R., Byrne, F. J., Devonshire, A. L., Henneberry, T. J., Castle, N. Prabhaker, Castle, S., Anthony, N. M., Constant, R. H. ffrench, Sachs, Y., Fehmy, M., Hegab, A. H., Moawad, G. M., Nichols, R. L., Chu, C. C., Watson, T. F., Davidson, Elizabeth W., Patron, Rufino B. R., Mitich, Dusan, Stansly, P. A., Liu, T. X., Veierov, D., Aharonson, N., Eliyahu, Miriam, Fenigstein, Annie, Kletter, E., Munthali, D. C., Berlinger, M. J., Mordechi, Sarah Lebiush, Ausher, Reuben, Diehl, J. W., Husman, S. H., Kravchenko, Vasilyi, Arnal, Eustaquio, Ramos, Fidel, Fridja, Devorah, Ferrentino, G. W., Caballero, R., Nicholson, W. F., Senn, R., Fluckiger, C. R., Puri, S. N., Bhosle, B. B., Fartade, M. K., Kolhal, R. N., Butler, G. D., and Gupta, G. P.

Published
1994
Full Text
View/download PDF

44. Editorial

Author

Legg, J. P.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results